13F Holdings
中文EN

CCCC C4 Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1662579 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY7.2%
TTM net income YoY23.5%
TTM EPS YoY62.3%
Revenue 3-yr CAGR16.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-315.9%
Net margin-282.2%
FCF margin-247.1%
EBITDA margin-311.2%

Returns

ROE-47.6%
ROA-30.5%
ROIC (approx.)-55.3%
Asset turnover0.11x

Leverage & solvency

Liabilities / assets31.2%
Debt / equity0.00x
Current ratio5.17x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio-3.8%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$35.95M$35.58M$20.76M$31.10M$45.78M
R&D expense$104.24M$110.64M$117.71M$117.84M$94.67M
SG&A expense$36.20M$42.12M$42.08M$42.79M$33.25M
Operating income-$115.22M-$119.61M-$139.03M-$129.53M-$82.13M
Pretax income-$104.87M-$105.19M-$131.21M-$128.18M-$83.89M
Income tax$121,000$131,000$1.28M$0$0
Net income-$104.99M-$105.32M-$132.49M-$128.18M-$83.89M
EBITDA-$113.26M-$117.80M-$137.15M-$127.86M-$80.64M
EPS (basic)-1.27-1.52-2.67-2.62-1.82
EPS (diluted)-1.27-1.52-2.67-2.62-1.82
Weighted avg. shares (diluted)82.89M69.37M49.64M48.86M46.04M
Balance sheet
Cash & equivalents$74.60M$58.94M$130.03M$33.03M$79.40M
Short-term investments————$233.16M
Receivables$2.40M$3.10M$11.80M$1.47M$5.72M
Current assets$258.11M$257.77M$271.19M$287.56M$325.69M
PP&E, net$4.74M$5.84M$7.13M$7.40M$3.11M
Total assets$359.07M$349.60M$376.45M$430.84M$506.76M
Current liabilities$33.03M$45.18M$42.77M$44.55M$51.25M
Short-term debt——$0$2.29M$0
Long-term debt——$0$9.20M$10.77M
Total debt——$0$11.48M$10.77M
Total liabilities$102.49M$133.62M$130.34M$141.61M$117.16M
Shareholders' equity$256.59M$215.99M$246.11M$289.23M$389.61M
Net debt——-$130.03M-$21.55M-$68.64M
Shares outstanding96.91M70.63M60.47M48.97M48.69M
Cash flow statement
Operating cash flow-$98.69M-$65.16M-$106.84M-$105.94M-$86.97M
Capital expenditure$607,000$180,000$1.71M$5.50M$1.28M
Free cash flow-$99.30M-$65.34M-$108.55M-$111.44M-$88.24M
Investing cash flow-$8.60M-$51.27M$158.35M$58.42M-$189.34M
Financing cash flow$126.40M$45.34M$45.49M$1.15M$171.40M
Depreciation & amortization$1.96M$1.82M$1.88M$1.68M$1.49M
Stock-based compensation$19.10M$29.66M$27.23M$30.02M$21.51M
Share buybacks$193,000$194,000$110,000$0—

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.